Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $135.07M
• Dividend Yield: N/A
• Average Volume (3M): 7.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -37.13%
• EPS Growth: 40.47%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 336,494,480
• 10 Day Avg. Volume: 4,237,466
• 30 Day Avg. Volume: 7,646,780
• PEG Ratio: 0.03
• Price to Book (P/B): 9.04
• Price to Sales (P/S): 3.56
• P/FCF Ratio: -3.05
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 3.95
• Enterprise Value/Gross Profit: 3.95
• Enterprise Value/Ebitda: -1.26
• 1Y Price Target: $3.75
• Price Target Upside: 837.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $0.40 ▼(-0.25% Downside)

Overall score reflects weak financial fundamentals (sharp revenue decline, ongoing losses and cash burn, and reduced balance sheet flexibility) partially offset by a constructive earnings-call update highlighting Fabry clinical progress and supportive FDA feedback. Technicals are neutral-to-weak and valuation is constrained by negative earnings and no dividend.

Positive Factors

FDA Endorsement

The FDA's acceptance of a rolling submission for ST-920 indicates regulatory support, enhancing the potential for accelerated approval and market entry, which could significantly boost Sangamo's market position and revenue prospects in the gene therapy space.

Pipeline Advancement

Advancing the neurology pipeline with patient enrollment in the STAND study demonstrates Sangamo's commitment to expanding its therapeutic offerings, potentially leading to new revenue streams and strengthening its competitive position in the biotech industry.

Extended Cash Runway

An extended cash runway provides Sangamo with financial stability to continue its R&D activities and strategic initiatives without immediate pressure to secure additional funding, supporting long-term operational sustainability.

Negative Factors

Declining Revenue

A significant decline in revenue reflects challenges in monetizing its pipeline and partnerships, which could hinder Sangamo's ability to invest in future growth and maintain competitive advantages in the biotech industry.

Negative Cash Flow

Ongoing negative cash flow indicates difficulties in generating sufficient cash from operations, which may limit Sangamo's ability to fund R&D and strategic initiatives, impacting its long-term growth prospects.

Funding Challenges

The need for additional funding highlights financial vulnerabilities that could constrain Sangamo's ability to advance its pipeline and capitalize on market opportunities, potentially affecting its competitive position and growth trajectory.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo Biosciences generates revenue through a combination of partnerships, collaborations, and grants with pharmaceutical and biotechnology companies, as well as government funding. The company often enters into strategic collaborations to develop its gene therapy programs, which can include upfront payments, milestone payments based on development progress, and royalties on future product sales. Additionally, Sangamo may receive funding from research grants and public sector initiatives aimed at advancing gene-editing technologies. Its revenue model is heavily reliant on the successful development and commercialization of its therapeutic candidates, alongside leveraging its proprietary technologies for new partnerships.

Sangamo Biosciences Financial Statement Overview

Summary

Financial profile remains high-risk: TTM revenue declined sharply (~60%), profitability is deeply negative, and operating/free cash flow are still negative (ongoing burn). Balance sheet flexibility has weakened with higher leverage (debt-to-equity above 1.0) after equity contraction, though losses and cash burn have improved versus 2022–2023.

Income Statement

TTM (Trailing-Twelve-Months) revenue is down sharply (about 60% decline vs. the prior period), highlighting a weakening top-line backdrop. While gross profit is high in the most recent periods, profitability remains deeply negative: EBIT, EBITDA, and net income are all meaningfully in the red, and net margins are strongly negative across the timeline. Losses have improved versus 2023’s very large deficit, but the business is still far from breakeven and earnings quality remains a key concern.

Balance Sheet

Leverage has risen as equity has contracted materially, with debt-to-equity moving from low levels historically to above 1.0 in the most recent periods—signaling a weaker capital cushion. Total debt is not extremely large in absolute terms, but the balance sheet has less flexibility given the small equity base and continued losses (negative returns on equity). Overall, solvency risk is higher than in prior years, even if the company is not currently heavily debt-funded by nominal debt dollars.

Cash Flow

Cash generation remains pressured: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) and recent annual periods, indicating ongoing cash burn. The magnitude of cash outflow has improved significantly versus 2022–2023, but the company is still consuming cash to operate. Free cash flow tracking close to net income mainly reflects that both are negative, rather than strong cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.88M	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	32.88M	57.80M	176.23M	99.19M	110.70M	-62.45M
EBITDA	-102.81M	-89.09M	-96.80M	-189.17M	-165.70M	-123.87M
Net Income	-108.91M	-97.94M	-257.83M	-192.28M	-178.29M	-121.00M
Balance Sheet
Total Assets	88.64M	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	30.53M	41.92M	81.00M	277.63M	376.55M	641.42M
Total Debt	25.42M	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	82.40M	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	6.24M	22.77M	82.89M	294.96M	375.34M	498.23M
Cash Flow
Free Cash Flow	-76.40M	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-76.16M	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	1.24M	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	62.94M	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.45, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.46 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$145.86M	7.06	19.23%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMO	49 Neutral	$135.07M	-0.91	-480.02%	―	-37.13%	40.47%
CRBU	47 Neutral	$136.46M	-0.86	-74.28%	―	-19.00%	-2.72%
CABA	46 Neutral	$211.78M	-0.87	-101.06%	―	―	-17.21%
APLT	43 Neutral	$14.47M	-1.00	-680.47%	―	―	―
ELTX	43 Neutral	$144.29M	-2.43	―	―	―	17.36%

Sangamo Biosciences Corporate Events

Sangamo Biosciences Granted Nasdaq Compliance Extension

On October 29, 2025, Sangamo Therapeutics, Inc. received an extension from Nasdaq until April 27, 2026, to comply with the minimum bid price requirement of $1.00 per share for its continued listing on The Nasdaq Capital Market. This extension follows a previous notice on April 30, 2025, indicating non-compliance with the requirement. The company aims to meet the requirement by the deadline, but failure to do so may result in delisting, with the option to appeal the decision.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.